View in EDS PDF Full Text

A phase II study of buparlisib in relapsed or refractory thymomas.

Saved in:
Bibliographic Details
Title: A phase II study of buparlisib in relapsed or refractory thymomas.
Authors: Abu Zaid MI; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Radovich M; Caris Life Science, Dallas, TX, United States., Althouse S; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Liu H; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Spittler AJ; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Solzak J; Caris Life Science, Dallas, TX, United States., Badve S; Department of Biostatistics, Emory University, Atlanta, GA, United States., Loehrer PJ Sr; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
Source: Frontiers in oncology [Front Oncol] 2022 Oct 18; Vol. 12, pp. 891383. Date of Electronic Publication: 2022 Oct 18 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36330484
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase II study of buparlisib in relapsed or refractory thymomas.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Abu+Zaid+MI%22">Abu Zaid MI</searchLink>; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Radovich+M%22">Radovich M</searchLink>; Caris Life Science, Dallas, TX, United States.<br /><searchLink fieldCode="AU" term="%22Althouse+S%22">Althouse S</searchLink>; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Liu+H%22">Liu H</searchLink>; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Spittler+AJ%22">Spittler AJ</searchLink>; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Solzak+J%22">Solzak J</searchLink>; Caris Life Science, Dallas, TX, United States.<br /><searchLink fieldCode="AU" term="%22Badve+S%22">Badve S</searchLink>; Department of Biostatistics, Emory University, Atlanta, GA, United States.<br /><searchLink fieldCode="AU" term="%22Loehrer+PJ+Sr%22">Loehrer PJ Sr</searchLink>; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2022 Oct 18; Vol. 12, pp. 891383. <i>Date of Electronic Publication: </i>2022 Oct 18 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36330484
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2022.891383
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 891383
    Titles:
      – TitleFull: A phase II study of buparlisib in relapsed or refractory thymomas.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Abu Zaid MI
      – PersonEntity:
          Name:
            NameFull: Radovich M
      – PersonEntity:
          Name:
            NameFull: Althouse S
      – PersonEntity:
          Name:
            NameFull: Liu H
      – PersonEntity:
          Name:
            NameFull: Spittler AJ
      – PersonEntity:
          Name:
            NameFull: Solzak J
      – PersonEntity:
          Name:
            NameFull: Badve S
      – PersonEntity:
          Name:
            NameFull: Loehrer PJ Sr
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 10
              Text: 2022 Oct 18
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1